Erratum to: Single-agent bevacizumab is an effective treatment in recurrent glioblastoma

Ilhan Hacibekiroglu · Hilmi Kodaz · Bulent Erdogan · Esma Turkmen ·
Melike Ozcelik · Asim Esenkaya · Haci Mehmet Saygi · Sernaz Uzunoglu ·
Irfan Cicin

Published online: 19 March 2015
© Springer Science+Business Media New York 2015

Erratum to: Med Oncol (2015) 32:12
DOI 10.1007/s12032-014-0460-3

An error was inadvertently missed by the author in the original publication, and it has been corrected with this erratum.

“PFS of female patients was 6.2 (0–14.4)” should be replaced with “3.4 (0–8.8)” in Table 2 on page 5.

The online version of the original article can be found under doi:[10.1007/s12032-014-0460-3](https://doi.org/10.1007/s12032-014-0460-3).

I. Hacibekiroglu (✉) · H. Kodaz · B. Erdogan · E. Turkmen ·
S. Uzunoglu · I. Cicin
Department of Medical Oncology, Faculty of Medicine,
Trakya University, 22030, Edirne, Turkey
e-mail: ilhanhbbo@hotmail.com

M. Ozcelik
Department of Medical Oncology, Kartal Training and Research
Hospital, Istanbul, Turkey

A. Esenkaya
Department of Radiology, Faculty of Medicine,
Trakya University, Edirne, Turkey

H. M. Saygi
Department of Neurosurgery, Faculty of Medicine,
Trakya University, Edirne, Turkey